查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593862

肝病治疗市场：按治疗方法、最终用户划分 - 2025-2030 年全球预测

Liver Diseases Therapeutics Market by Treatment (Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids), End User (Ambulatory Surgery Centers, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肝病治疗市场规模为167.7亿美元，预计2024年将达181.2亿美元，复合年增长率为8.16%，2030年将达290.4亿美元。

肝病治疗市场包括开发和使用药物和治疗方法来治疗各种肝病，例如肝炎、肝癌和肝硬化。全球肝臟疾病盛行率不断上升，推动了对这些治疗的需求，而饮酒、肥胖和肝炎感染增加等生活方式因素往往会加剧这种疾病。治疗是在预防、治疗和支持性护理的框架内进行的，最终用户包括医院、临床研究中心和门诊病人设施。关键的成长要素包括药物治疗的进步、对肝病病理生理学的更好理解以及新兴市场医疗保健服务的扩展。精准医疗和个人化治疗的采用、生物技术的使用以及协作研发的推广存在潜在的商机。阻碍市场成长的挑战包括高昂的治疗成本、肝病发病机制的复杂性以及与药物核准相关的监管障碍。此外，低收入地区的医疗保健基础设施薄弱，限制了治疗的获得和接受度。在技​​术创新方面，具有成长潜力的研究领域包括生技药品、基因治疗和针对肝功能恢復的再生医学方法。探索非侵入性诊断工具并利用巨量资料分析进行个人化治疗计划也可以提供竞争优势。市场动态是不稳定的，竞争格局受到製药进步、合併和策略联盟的影响。这个广阔而复杂的市场需要持续的投资和透彻的了解，才能有效地利用新的治疗方法突破。为了缓解限制，相关人员应专注于具有成本效益的药物开发、稳健的临床试验和加强病患教育，以降低疾病进展率。加强製药公司、学术机构和政府之间的合作将对克服现有障碍和创造永续的市场环境发挥至关重要的作用。整合最新创新并响应市场需求的适应性业务策略，同时优先考虑监管合规性和道德考虑，对于肝病治疗业务的持续成长仍然至关重要。

主要市场统计
基准年[2023] 167.7亿美元
预测年份 [2024] 181.2亿美元
预测年份 [2030] 290.4亿美元
复合年增长率（%） 8.16%

市场动态：快速发展的肝病治疗市场的关键市场洞察

供需的动态交互作用正在改变肝病治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球肝病迅速增加
    • 政府和私人组织加强提高意识和疫苗接种计划
    • 生活方式的改变，例如饮酒和吸烟
  • 市场限制因素
    • 对药物副作用的担忧
  • 市场机会
    • 预防和治疗肝病的持续研究和开发活动
    • 治疗药物专利到期增加
  • 市场挑战
    • 与严格的政府法规和研发相关的高成本

波特五力：驾驭肝病治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肝病治疗市场的外部影响

外部宏观环境因素在塑造肝病治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肝病治疗市场的竞争状况

肝病治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肝病治疗市场供应商的绩效评估

FPNV定位矩阵是评估肝病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划肝病治疗市场的成功之路

肝病治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球肝病发生率飙升
      • 政府和私人组织加强宣传和疫苗接种计划
      • 生活方式的改变，例如饮酒和吸烟
    • 抑制因素
      • 对可能的药物副作用的担忧
    • 机会
      • 预防和治疗肝病的持续研究和开发活动
      • 治疗药物专利到期增加
    • 任务
      • 严格的政府监管和高昂的研发成本
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗方式分類的肝病治疗市场

  • 抗病毒药物
  • 化疗药物
  • 皮质类固醇
  • 免疫球蛋白
  • 免疫抑制药物
  • 标靶治疗

第七章肝病治疗市场：依最终使用者分类

  • 门诊手术中心
  • 医院

第八章北美与南美洲肝病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肝病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的肝病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals, Inc.
  • Endo International PLC
  • F. Hoffmann-La Roche AG
  • Gilead Science Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Sanofi SA
Product Code: MRR-437A5D08AE2A

The Liver Diseases Therapeutics Market was valued at USD 16.77 billion in 2023, expected to reach USD 18.12 billion in 2024, and is projected to grow at a CAGR of 8.16%, to USD 29.04 billion by 2030.

The liver diseases therapeutics market involves the development and use of drugs and treatments to address a range of liver conditions, including hepatitis, liver cancer, and cirrhosis, among others. The necessity for these therapeutics is driven by the rising prevalence of liver conditions globally, often exacerbated by lifestyle factors such as alcohol consumption, obesity, and the increasing incidence of hepatitis infections. Applications span across preventive, curative, and supportive treatment frameworks, with end-users including hospitals, clinical research centers, and outpatient facilities. Key growth factors include advancements in pharmacotherapy, an increased understanding of liver disease pathophysiology, and expanding healthcare access in emerging markets. Potential opportunities lie in adopting precision medicine and personalized therapeutics, leveraging biotechnology, and pursuing collaborations for research development. Challenges impeding market growth include high treatment costs, the complexity of liver disease etiology, and regulatory hurdles associated with drug approval. Moreover, inconsistent healthcare infrastructure in low-income regions limits therapeutic accessibility and adoption. For innovation, research areas promising growth prospects include biologics, gene therapy, and regenerative medicine approaches targeting liver function restoration. Exploring non-invasive diagnostic tools and leveraging big data analytics for personalized treatment plans can also offer competitive advantages. Market dynamics are fluid, with competitive landscapes influenced by pharmaceutical advancements, mergers, and strategic partnerships. This broad and complex market requires ongoing investment and thorough understanding to capitalize on emerging therapeutic breakthroughs effectively. To mitigate limitations, stakeholders should focus on cost-effective drug development, robust clinical trials, and enhancing patient education to reduce disease progression rates. Enhanced collaboration among pharma companies, academic institutions, and governments will play a crucial role in overcoming existing barriers and creating a sustainable market environment. An adaptable business strategy, which integrates recent innovations and responds to market needs while prioritizing regulatory compliance and ethical considerations, remains pivotal for sustained business growth in liver diseases therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 16.77 billion
Estimated Year [2024] USD 18.12 billion
Forecast Year [2030] USD 29.04 billion
CAGR (%) 8.16%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Diseases Therapeutics Market

The Liver Diseases Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the incidences of liver diseases worldwide
    • Increasing government and private organizations initiatives toward awareness and vaccination programs
    • Changing lifestyles such as consumption of alcohol and smoking
  • Market Restraints
    • Concerns over probable side effects of the medication
  • Market Opportunities
    • Ongoing research and development activities for prevention and cure of liver diseases
    • Increasing patent expiration of therapeutics
  • Market Challenges
    • Strict government regulations and high cost involved in R&D

Porter's Five Forces: A Strategic Tool for Navigating the Liver Diseases Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Diseases Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Diseases Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Diseases Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Diseases Therapeutics Market

A detailed market share analysis in the Liver Diseases Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Diseases Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Diseases Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Diseases Therapeutics Market

A strategic analysis of the Liver Diseases Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Diseases Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Endo International PLC, F. Hoffmann-La Roche AG, Gilead Science Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Protagonist Therapeutics, Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Liver Diseases Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids, Immunoglobulin, Immunosuppressant Drugs, and Targeted Therapy.
  • Based on End User, market is studied across Ambulatory Surgery Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the incidences of liver diseases worldwide
      • 5.1.1.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
      • 5.1.1.3. Changing lifestyles such as consumption of alcohol and smoking
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over probable side effects of the medication
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development activities for prevention and cure of liver diseases
      • 5.1.3.2. Increasing patent expiration of therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government regulations and high cost involved in R&D
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Diseases Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Anti Viral Drugs
  • 6.3. Chemotherapy Drugs
  • 6.4. Corticosteroids
  • 6.5. Immunoglobulin
  • 6.6. Immunosuppressant Drugs
  • 6.7. Targeted Therapy

7. Liver Diseases Therapeutics Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgery Centers
  • 7.3. Hospitals

8. Americas Liver Diseases Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Diseases Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Diseases Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Dicerna Pharmaceuticals, Inc.
  • 6. Endo International PLC
  • 7. F. Hoffmann-La Roche AG
  • 8. Gilead Science Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co. Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Protagonist Therapeutics, Inc.
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023